Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × trilaciclib × Gastrointestinal × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Colorectal Neoplasms 1

Interventions

Fluorouracil 306 Oxaliplatin 257 Leucovorin 233 Capecitabine 196 Irinotecan 143 Gemcitabine 127 Cisplatin 126 Bevacizumab 117 Radiotherapy 72 Paclitaxel 63 Folfox protocol 56 Cetuximab 54 Drug Therapy 46 Sorafenib 45 Docetaxel 41 S 1 (combination) 40 Neoadjuvant Therapy 37 Chemotherapy, Adjuvant 37 pembrolizumab 36 130-nm albumin-bound paclitaxel 27 Surgical Procedures, Operative 26 regorafenib 25 lenvatinib 24 XELOX 24 Panitumumab 24 Radiation 23 Nivolumab 22 trifluridine tipiracil drug combination 21 atezolizumab 21 Carboplatin 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡